Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Thrombosis and Haemostasis

• Publication date

  2008-04-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1160/TH07-11-0654PMID 18449416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenicity of therapeutic proteins. Part 1: impact of product handling.

  2007cited by this paper
• A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

  2007cited by this paper
• Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

  2007cited by this paper
• Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes.

  2007cited by this paper
• Current options for the treatment of idiopathic thrombocytopenic purpura.

  2007cited by this paper
• Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates

  2007cited by this paper
• Immunogenicity of therapeutic proteins. Part 2: impact of container closures.

  2007cited by this paper
• Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

  2006cited by this paper
• Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells

  2006cited by this paper
• Biopharmaceutical benchmarks 2006

  2006cited by this paper
• Recombinant vs. plasma‐derived products, especially those with intact VWF, regarding inhibitor development

  2006cited by this paper
• Effects of protein aggregates: An immunologic perspective

  2006cited by this paper
• Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.

  2005cited by this paper
• Immunogenicity of engineered antibodies.

  2005cited by this paper
• Therapeutic insulins and their large-scale manufacture

  2005cited by this paper
• Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure

  2005cited by this paper
• Protein drug stability: a formulation challenge

  2005cited by this paper
• Silicone oil induced aggregation of proteins.

  2005cited by this paper
• Stability of Ala 125 recombinant human interleukin‐2 in solution

  2005cited by this paper
• Glycoform characterization of intact erythropoietin by capillary electrophoresis‐electrospray‐time of flight‐mass spectrometry

  2005cited by this paper
• Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays

  2005cited by this paper
• Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

  2005cited by this paper
• Stability of Protein Formulations: Investigation of Surfactant Effects by a Novel EPR Spectroscopic Technique

  2004cited by this paper
• Structure-Immunogenicity Relationships of Therapeutic Proteins

  2004cited by this paper
• Relationships between factor VIII:Ag and factor VIII in recombinant and plasma‐derived factor VIII concentrates

  2004cited by this paper
• Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.

  2004cited by this paper
• Characterizing biological products and assessing comparability following manufacturing changes

  2004cited by this paper
• Appropriate glycosylation of recombinant proteins for human use

  2004cited by this paper
• Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders.

  2004cited by this paper
• Helper T-cell-regulated B-cell immunity.

  2003cited by this paper
• Prophylaxis in factor IX deficiency product and patient variation

  2003cited by this paper
• Shifting paradigms: biopharmaceuticals versus low molecular weight drugs.

  2003cited by this paper
• Helper T cell-regulated B cell immunity.

  2003cited by this paper
• Factor XI deficiency--from molecular genetics to clinical management.

  2003cited by this paper
• Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.

  2003cited by this paper
• Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• The immunogenicity of biopharmaceuticals

  2003cited by this paper
• Inhibitor development in correlation to factor VIII genotypes

  2002cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency

  2002cited by this paper
• Peroxide formation in polysorbate 80 and protein stability.

  2002cited by this paper
• PEGylated antibodies and antibody fragments for improved therapy: a review.

  2002cited by this paper
• Antibodies against rHuEPO: native and recombinant.

  2002cited by this paper
• Immunogenicity of therapeutic proteins: clinical implications and future prospects.

  2002cited by this paper
• Immunogenicity of rDNA-derived pharmaceuticals.

  2002cited by this paper
• Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.

  2002cited by this paper
• Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.

  2002cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• Mono-N-terminal poly(ethylene glycol)-protein conjugates.

  2002cited by this paper
• Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles

  2002cited by this paper
• A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.

  2002cited by this paper
• Pure red-cell aplasia and recombinant erythropoietin.

  2002cited by this paper
• Inverse Relationship of Protein Concentration and Aggregation

  2002cited by this paper
• On the treatment of hemorrhage in patients with hemophilia and associated inhibitors

  2001cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin.

  2001cited by this paper
• Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis

  2001cited by this paper
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Advances in Escherichia coli production of therapeutic proteins.

  2001cited by this paper
• In Situ Study of Insulin Aggregation Induced by Water-Organic Solvent Interface

  2001cited by this paper
• Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.

  2001cited by this paper
• Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune Tolerance

  2001cited by this paper
• Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

  2001cited by this paper
• Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

  2001cited by this paper
• Pegylation: a novel process for modifying pharmacokinetics.

  2001cited by this paper
• Industrial choices for protein production by large-scale cell culture.

  2001cited by this paper
• Abciximab Readministration: Results of the ReoPro Readministration Registry

  2001cited by this paper
• Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens.

  2001cited by this paper
• Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

  2001cited by this paper
• Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C

  2001cited by this paper
• Interferon-beta (IFN-β) antibodies in interferon-β1a-and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo

  2001cited by this paper
• Peptide and protein PEGylation: a review of problems and solutions.

  2001cited by this paper
• Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

  2001cited by this paper
• Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.

  2000cited by this paper
• B‐cell activation by T‐cell‐independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms

  2000cited by this paper
• Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

  2000cited by this paper
• Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells

  2000cited by this paper
• Prevention and treatment of factor VIII inhibitors in murine hemophilia A.

  2000cited by this paper
• Biopharmaceutical benchmarks

  2000cited by this paper
• Recombinant erythropoietin in urine

  2000cited by this paper
• Recombinant erythropoietin in urine.

  2000cited by this paper
• Electrospray time-of-flight mass spectrometry of the intact MS2 virus capsid

  2000cited by this paper
• Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

  2000cited by this paper
• Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

  2000cited by this paper
• Stabilization of insulin against agitation-induced aggregation by the GMO cubic phase gel.

  1999cited by this paper
• Development of antibodies to interferon beta in patients: technical and biological aspects.

  1999cited by this paper
• Metabolic effects on recombinant interferon‐γ glycosylation in continuous culture of Chinese hamster ovary cells

  1999cited by this paper
• Rapid structural characterisation of a murine monoclonal IgA alpha chain: heterogeneity in the oligosaccharide structures at a specific site in samples produced in different bioreactor systems.

  1999cited by this paper
• Instability, stabilization, and formulation of liquid protein pharmaceuticals.

  1999cited by this paper
• Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects.

  1999cited by this paper
• Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.

  1999cited by this paper
• Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

  1999cited by this paper
• The Role of Genetics in Inhibitor Formation

  1999cited by this paper
• Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates

  1999cited by this paper
• Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions.

  1998cited by this paper
• Effects of deleting A19 tyrosine from insulin.

  1998cited by this paper
• Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII.

  1998cited by this paper
• Small Deletion/Insertion Mutations within Poly-A Runs of the Factor VIII Gene Mitigate the Severe Haemophilia A Phenotype

  1998cited by this paper
• The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

  1998cited by this paper
• Efects of deleting A19 tyrosine form insulin

  1998cited by this paper

• Inhibitors of Hemophilia A in Children Less Than 15 Years Attending Children Welfare Hospital in Baghdad

  2021cites this paper
• Recombinant FimH, a fimbrial tip adhesin of Vibrio parahaemolyticus, elicits mixed T helper cell response and confers protection against Vibrio parahaemolyticus challenge in murine model.

  2021cites this paper
• De novo design of ACE2 protein decoys to neutralize SARS-CoV-2

  2020cites this paper
• De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

  2020cites this paper
• Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs

  2020cites this paper
• Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?

  2020cites this paper
• Biochemical and in silico evaluation of recombinant E. coli aminopeptidase and in vitro processed human interferon α-2b.

  2018cites this paper
• Peptides for biopharmaceutical applications

  2018cites this paper
• Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

  2016influential citation
• Biopharmaceutics of NCEs and NBEs

  2016cites this paper
• SEGURANÇA E EFICÁCIA CLÍNICA NA SUBSTITUIÇÃO DE MEDICAMENTOS BIOSSIMILARES: AVALIAÇÃO CRÍTICA DA BIBLIOGRAFIA AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION

  2015cites this paper
• Investigation on the Action of Two Types of Biological Active Substances to the Soluble Proteins that Enriched the Animal’s Blood Serum

  2015cites this paper
• Direct Site-Specific Glycoform Identification and Quantitative Comparison of Glycoprotein Therapeutics: Imiglucerase and Velaglucerase Alfa

  2014cites this paper
• Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance

  2014cites this paper
• Direct approach for qualitative and quantitative characterization of glycoproteins using tandem mass tags and an LTQ Orbitrap XL electron transfer dissociation hybrid mass spectrometer.

  2013cites this paper
• An albumin-binding domain as a scaffold for bispecific affinity proteins

  2012cites this paper
• Safety of Biotherapeutics

  2012cites this paper
• Physicochemical strategies for inhibition of amyloid fibril formation: an overview of recent advances.

  2012cites this paper
• COCERIG ISSUES WITH BIOSIMILARS: AOVERVIEW

  2011cites this paper
• Impact of product-related factors on immunogenicity of biotherapeutics.

  2011cites this paper
• High‐throughput measurement, correlation analysis, and machine‐learning predictions for pH and thermal stabilities of Pfizer‐generated antibodies

  2011cites this paper
• Biotechnology-Derived Medicines: What are They? A Pharmacological and a Historical Perspective

  2010cites this paper
• Separation by hydrophobic interaction chromatography and structural determination by mass spectrometry of mannosylated glycoforms of a recombinant transferrin-exendin-4 fusion protein from yeast.

  2010cites this paper
• Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.

  2010cites this paper
• Safety of therapeutic monoclonal antibodies.

  2010cites this paper
• Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients

  2009cites this paper
• Biosimilars--science, status, and strategic perspective.

  2009cites this paper
• Molecular evolution of a C5aR antagonist against inflammatory disease

  2009cites this paper
• Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model.

  2009cites this paper
• Engineered protein scaffolds as next-generation antibody therapeutics.

  2009cites this paper
• Therapeutic properties and safety of recombinant factor VIII and factor IX.

  2009cites this paper
• Immunotoxicity of monoclonal antibodies

  2009cites this paper
• Risk factors for inhibitor formation in haemophilia: a prevalent case–control study

  2009cites this paper
• Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.

  2009cites this paper
• Soft materials to treat central nervous system injuries: evaluation of the suitability of non-mammalian fibrin gels.

  2009cites this paper
• Clinical immunotoxicity of therapeutic proteins

  2008cites this paper
• Current use of biologicals in thrombosis and haemostasis

  2008cites this paper
• Theme Issue Editorial

  2008cites this paper